The US Food and Drug Administration (FDA) has approved an expanded indication for MED-EL’s SYNCHRONY cochlea implants in infants aged seven months and older with bilateral sensorineural hearing loss ...
The global sleep apnea implants market is projected to expand at a compound annual growth rate (CAGR) of approximately 10% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results